ACI's Inaugural Summit on GLP-1 Law & Policy

Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking in American Conference Institute’s (ACI) Inaugural Summit on GLP-1 Law & Policy on July 24. Serving as the conference co-chair, Faget will explore how stakeholders can navigate risk and understand new regulation in the weight loss drug market.

The weight loss drug market, now exceeding US$100 billion, is rapidly expanding. ACI’s conference will feature industry leaders for a discussion focused on the opportunities and challenges of this booming industry.

Key event topics include:

• Regulatory Compliance & Market Strategies
  • Navigating U.S. Food & Drug Administration (FDA), Federal Trade Commission (FTC), and Centers for Medicare & Medicaid Services (CMS) oversight under a new administration.
• Intellectual Property & Exclusivity Risks
  • Understanding how patent cliffs and biosimilar competition could reshape the market.
• Compounding & Telehealth Disruption
  • Examining regulatory battles over compounded GLP-1 drugs and their impact on traditional pharma.
• Reimbursement & Payer Strategies
  • Addressing insurer pushback, Medicare drug pricing negotiations, and pharmacy benefit manager strategies.
• Litigation & Liability Risks
  • Preparing for mass tort risks, product liability concerns, and class action lawsuits.
• Investment & Strategic Deals.
  • Exploring M&A trends, venture capital outlook, and the licensing models influencing the future of weight loss pharmaceuticals.